Abstract
Diabetic nephropathy (DN) is a major cause of type 2 diabetes mellitus (T2DM) mortality. Innate immunity has been shown to be closely associated with the occurrence and progression of T2DM-associated complications. In this study, we investigated the expression of Toll-like receptor 4 (TLR4) and CD14+CD16+ monocytes in patients with T2DM and DN patients with uremia and TLR4 response to lipopolysaccharide (LPS), and to further explore the potential effects of inflammatory immune response in T2DM and DN uremia. Thirty DN patients with uremia, 28 T2DM patients, and 20 healthy volunteers were enrolled for the determination of CD14+CD16+ fluorescence intensity and TLR4 expression on monocytes by using peripheral blood flow cytometry. Serum C-reactive protein (CRP) level was determined by using the immunoturbidimetry. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with LPS for 24 h. monocytes were collected to detect NF-κB p65 and phosphorylated STAT5(p-STAT5) expressions by using Western blotting. Supernatants were sampled for the determination of interleukin-6 (IL-6) concentration by using ELISA. Compared to normal control, T2DM patients and DN uremic patients had a significantly higher CD14+CD16+ fluorescence intensity, TLR4 expression, serum IL-6 and CRP level, whilst these biomarkers were more upregulated in DN uremic patients than in T2DM patients. Following the exposure to LPS, PBMCs showed a significant upregulation in NF-κB-p65 and p-STAT5 expression and a remarked increase in Supernatants IL-6 level, in a positive correlation with disease severity. Our results suggest that the disturbance in proinflammatory CD14+CD16+ monocytes occurs in T2DM and DN uremic patients. Such immunological dysfunction may be related to the activation of TLR4/NF-κB and STAT5 signaling pathways underlying the immune abnormalities of CD14+CD16+ monocytes.
Similar content being viewed by others
References
Navarro-González, J.F., and C. Mora-Fernández. 2008. The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrologists 19(3): 433–442.
Ortiz-Muñoz, G., V. Lopez-Parra, O. Lopez-Franco, et al. 2010. Suppressors of cytokine signaling abrogate diabetic nephropathy. Journal of the American Society of Nephrologists 21: 763–772.
O’Connor, J.C., A. Satpathy, M.E. Hartman, et al. 2005. IL-β mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. Journal of Immunology 174(8): 4991–4997.
Ko, G.J., Y.S. Kang, S.Y. Han, et al. 2008. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology, Dialysis, Transplantation 23(9): 2750–2760.
Mora, C., and J.F. Navarro. 2006. Inflammation and diabetic nephropathy. Current Diabetes Reports 6(6): 463–468.
Navarro, J.F., and C. Mora. 2006. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. The Scientific World Journal 6: 908–917.
Tuttle, K.R. 2005. Linking metabolism and immunology: diabetic nephropathyis an inflammatory disease. Journal of the American Society of Nephrologists 16(6): 1537–1538.
Kikuchi, Y., T. Imakiire, M. Yamada, et al. 2005. Mizoribine reduces renal injury and macrophage infiltration in non-insulin dependent diabetic rats. Nephrology, Dialysis, Transplantation 20(8): 1573–1581.
Giulietti, A., E. van Etten, L. Overbergh, et al. 2007. Monocytes from type 2 diabetic patients have a pro-inflammatory profile 1,25-dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Research and Clinical Practice 77: 47–57.
Ruster, C., and G. Wolf. 2008. The role of chemokines and chemokine receptors in diabetic nephropathy. Frontiers of Bioscience 13: 944–955.
Chow, F., E. Ozols, D.J. Nikolic-Paterson, et al. 2004. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state, and progressive renal injury. Kidney International 65: 116–128.
Furuta, T., T. Saito, T. Ootaka, et al. 1993. The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases 21: 480–485.
Utimura, R., C.K. Fujihara, A.L. Mattar, et al. 2003. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney International 63: 209–216.
ManLi, L., G. Hua, and Q. Lin. 2009. The expression of TLR4 on peripheral blood monocytes from uremic patients with diabetic nephropathy and its relation with plasma MCP-1 concentration. China Immunology Journal 25(9): 848–850.
Hypponen, E., B.J. Boucher, D.J. Berry, et al. 2008. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross sectional study in the 1958 British Birth Cohort. Diabetes 57(2): 298–305.
Devaraj, S., J.-M. Yun, C.R. Duncan-Staley, et al. 2011. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. American Society for Clinical Pathology 135: 429–433.
Ozfirat, Z., and T.A. Chowdhury. 2010. Vitamin D deficiency and type 2 diabetes. Postgraduate Medical Journal 86: 18–25.
Kayaniyil, S., R. Vieth, R. Retnakaran, et al. 2010. Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 33(6): 1379–1381.
Di Cesar, D.J., R. Ploutz-Snyder, R.S. Weinstock, et al. 2006. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 29(1): 174.
Du, T., Z.-G. Zhou, S. You, et al. 2009. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Research and Clinical Practice 83(2): 208–214.
Sadeghi, K., B. Wessner, U. Laggner, et al. 2006. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. European Journal of Immunology 36: 361–370.
Ziegler-Heitbrock, L. 2007. The CD14+CD16+ blood monocytes: their role in infection and inflammation. Journal of Leukocyte Biology 81: 584–592.
Patino, R., J. Ibarra, A. Rodriguez, et al. 2000. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. The American Journal of Cardiology 85: 1288–1291.
Ulrich, C., G.H. Heine, M.K. Gerhart, et al. 2008. Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. American Journal of Transplantation 8(1): 103–110.
Barisione, C., S. Garibaldi, G. Ghigliotti, et al. 2010. CD14CD16 monocyte subset levels in heart failure patients. Disease Markers 28(2): 115–124.
Pettersson, A., A. Sabirsh, J. Bristulf, et al. 2005. Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes. Journal of Leukocyte Biology 77: 1018–1025.
Rogacev, K.S., S. Seiler, A.M. Zawada, et al. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. European Heart Journal 32(1): 84–92.
Tripathi, P., S. Kurtulus, S. Wojciechowski, et al. 2010. STAT5 is critical to maintain effector CD8+ T cell responses. Journal of Immunology 185: 2116–2124.
Acknowledgements
We thank Professor Qifu Li and Dr Lai Han for their cooperation in patient selection. This study was supported by the outstanding doctoral dissertation fund of Chongqing Medical University and the Key Project of Chongqing Municipal Health Bureau (2010-1-16).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, M., Gan, H., Shen, Q. et al. Proinflammatory CD14+CD16+ Monocytes are Associated with Microinflammation in Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy Uremia. Inflammation 35, 388–396 (2012). https://doi.org/10.1007/s10753-011-9374-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-011-9374-9